SCHEMBL13265487

SCHEMBL13265487

OC[C@H]1O[C@@H](n2cnc3c(Oc4cccc5cccnc45)ncnc32)C(O)C1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.62
MAPK1 P28482 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
ADORA2A P29274 2/20 0.55
ADORA1 P30542 2/20 0.55
DPP4 P27487 1/20 0.55
MEN1 O00255 1/20 0.55
SLC28A1 O00337 1/20 0.55
MAP3K7 O43318 1/20 0.55
SLC28A2 O43868 1/20 0.55
GAPDH P04406 1/20 0.55
ADORA2B P29275 1/20 0.55
STAT6 P42226 1/20 0.55
PI4KA P42356 1/20 0.55
KMT2A Q03164 1/20 0.55
PI4K2B Q8TCG2 1/20 0.55
DOT1L Q8TEK3 1/20 0.55
PI4K2A Q9BTU6 1/20 0.55
SLC28A3 Q9HAS3 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15165609 0.82 DNPH1 (0.44) SLC29A1ADORA1DNPH1ALDH1A1
SCHEMBL13239692 0.82 DNPH1 (0.44) SLC29A1ADORA1DNPH1ALDH1A1
SCHEMBL8651510 0.81 SLC29A1 (0.76) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL8651518 0.81 SLC29A1 (0.76) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL6887353 0.80 SLC29A1 (0.70) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL1979130 0.80 SLC29A1 (0.70) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL6903709 0.80 SLC29A1 (0.70) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL4081006 0.80 SLC29A1 (0.70) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL9142042 0.80 SLC29A1 (0.70) SLC29A1MAPK1SMN1; SMN2ADORA3ADORA2A
SCHEMBL13265435 0.80 ALDH1A1 (0.46) SLC29A1MAPK1DNPH1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179312-A1 CONVERTIBLE NUCLEOSIDE DERIVATIVES LAKSHMAN MAHESH K 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179312-A1 CONVERTIBLE NUCLEOSIDE DERIVATIVES PNP, NUDT1, NUDT14 SLC29A1 19/4885MAPK1 3830/4885SMN1; SMN2 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.